-
In recent weeks, Merit Medical Systems faced weaker sentiment after Wells Fargo downgraded its rating, prompting sustained selling by institutional investors.
-
This reaction stands in contrast to the company’s ongoing solid operations and financial position, highlighting a gap between fundamentals and market mood.
-
We’ll now examine how Wells Fargo’s downgrade and the resulting sentiment shift may influence Merit Medical Systems’ existing investment narrative.
Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
To be a shareholder in Merit Medical Systems, you need to believe in its role supplying single use devices for minimally invasive procedures and its ability to convert that demand into earnings over time. The Wells Fargo downgrade and subsequent selloff mainly affect short term sentiment; they do not appear to materially change the key near term catalyst, which remains securing WRAPSODY CIE reimbursement, or the biggest risk around execution in China and cost inflation.
The most relevant recent announcement in this context is Merit’s 2026 revenue guidance of US$1.610 billion to US$1.630 billion, implying mid single digit growth despite current headwinds. This outlook sits alongside the WRAPSODY reimbursement delay and higher operating expenses, which together frame how much room the company has to absorb sentiment shocks like the Wells Fargo downgrade while still supporting its longer term growth initiatives.
However, against this constructive setup, investors should be aware that continued weakness in China and volume based purchasing pressure could…
Read the full narrative on Merit Medical Systems (it’s free!)
Merit Medical Systems’ narrative projects $1.8 billion revenue and $197.2 million earnings by 2028. This requires 7.0% yearly revenue growth and about a $78 million earnings increase from $119.1 million today.
Uncover how Merit Medical Systems’ forecasts yield a $103.55 fair value, a 48% upside to its current price.
Two members of the Simply Wall St Community currently see fair value for Merit Medical Systems between US$82.26 and US$103.55, underscoring how far opinions can spread. Set against the recent sentiment driven pullback and the unresolved WRAPSODY CIE reimbursement delay, this spread invites you to compare several viewpoints on how short term risks could influence longer term outcomes.
Explore 2 other fair value estimates on Merit Medical Systems – why the stock might be worth as much as 48% more than the current price!
